Taysha Gene Therapies (TSHA) Misses Q2 EPS by 1c

Taysha Gene Therapies (NASDAQ: TSHA) reported Q2 EPS of ($0.09), $0.01 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $1.98 million versus the consensus estimate of $1.82 million.

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.

You May Also Be Interested In

• BMO Capital Resumes Global Net Lease (GNL), Upgrades to Outperform
• Investcorp Credit Management BDC, Inc. (ICMB) Misses Q2 EPS by 12c
• Bang Mai Fang files for 5M share IPO at $5-$6/sh